{{header-clinical-trials-navigation}} Early Detection of Prostate Cancer by Liquid Biopsy Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04556916 Sponsor: University Hospital, Montpellier Eligibility: Age: minimum 40 Years maximum N/A Gender: Male Inclusion Criteria: Patient : Men over 40 being suspicious of prostate cancer Subject with PSA ≥ 4 and designated for biopsy […]
{{header-clinical-trials-navigation}} A Phase 2 Comparison Study of 68Ga-PSMA-HBED-CC Positron Emission Tomography (PET)/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03439033 Sponsor: Weill Medical College of Cornell University Phase: Phase 2 Eligibility: Age: minimum 21 Years maximum N/A […]
{{header-clinical-trials-navigation}} A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03949517 Sponsor: Andrei Iagaru Phase: Phase 1/Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: All Inclusion Criteria: Known […]
{{header-clinical-trials-navigation}} A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03809078 Sponsor: Andrei Iagaru Phase: Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: All Inclusion Criteria: Suspected prostate cancer Planned […]
{{header-clinical-trials-navigation}} A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma Condition: Castration-Resistant Prostatic Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04077021 Sponsor: Calibr, a division of Scripps Research Phase: Phase 1 Eligibility: Age: minimum 18 […]
(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a Prostate Cancer Oligometastases session and a presentation by Dr. Angela Jia discussing whether we can cure oligorecurrent prostate cancer.
(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a Prostate Cancer Oligometastases session and a presentation by Dr. Matthew Deek discussing whether metastasis-directed therapy is the wave of the future for oligometastatic castration-resistant prostate cancer (CRPC).
To detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC) using multiparametric MRI. Participants with mRCC undergoing pre-surgical sunitinib therapy in the prospective NeoSun clinical trial (EudraCtNo: 2005-004502-82) were imaged before starting treatment, and after 12 days of sunitinib therapy using morphological MRI sequences, advanced diffusion-weighted imaging, measurements of R2* (related […]
Patients with advanced germ cell tumors (GCT) receiving cisplatin-based chemotherapy have high rates of thromboembolic events (TEE) which can negatively affect their overall survival. While primary TEE prophylaxis during chemotherapy may prevent these events, it is unclear which patients will benefit in this setting.
Clear cell renal cell carcinoma (ccRCC) is one of the most lethal urological malignancies, but the pathogenesis and prognosis of ccRCC remain obscure, which need to be better understand. Differentially expressed genes were identified and function enrichment analyses were performed using three publicly available ccRCC gene expression profiles downloaded from the Gene Expression Omnibus database.
